Galectin Therapeutics (GALT) ( (GALT) ) has released its Q3 earnings. Here is a breakdown of the information Galectin Therapeutics (GALT) presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer by targeting galectin proteins. In its latest earnings report for the quarter ended September 30, 2025, the company reported a net loss of $8.2 million, a decrease from the $11.2 million loss in the same period last year. The company’s total operating expenses were significantly reduced to $4.2 million from $9.1 million, primarily due to a decrease in research and development expenses.
The company’s financial performance highlights include a reduction in cash and cash equivalents to $11.5 million from $15.1 million at the end of 2024. Galectin Therapeutics has also seen an increase in its liabilities, with total liabilities rising to $136.4 million from $120.6 million. Despite the financial challenges, the company continues to secure funding, including a new $10 million line of credit from its chairman, Richard Uihlein.
Galectin Therapeutics’ strategic focus remains on advancing its clinical trials and drug development efforts. The company has been managing its resources carefully, as evidenced by the reduction in operating expenses and the strategic use of its line of credit. The company also issued new shares and warrants to raise additional capital, which is crucial for its ongoing research and development activities.
Looking ahead, Galectin Therapeutics is optimistic about its ability to continue its operations through June 2026, supported by its current cash reserves and the availability of its line of credit. The company plans to raise additional capital through various means, including potential collaborations and partnerships, to support its long-term strategic goals.